To include your compound in the COVID-19 Resource Center, submit it here.
Conatus began an open-label, U.S. Phase II trial to evaluate 25 mg oral emricasan twice daily for 28 days in about 20 patients
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury